StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30113% above fair value
$43.24+0.84 (+1.98%)

Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –

Teva Pharmaceutical Industries operating margin

Operating margin is operating income as a percentage of revenue.

Teva Pharmaceutical Industries's operating margin for the twelve months ending Jun 30, 2026 was 11.4%. For fiscal 2025 it was 12.5%, against -1.8% the year before. The highest annual figure on record is 25.5% in fiscal 2007.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202512.5%+14.3
FY2024Dec 31, 2024-1.8%−4.6
FY2023Dec 31, 20232.7%+17.5
FY2022Dec 31, 2022-14.7%−25.5
FY2021Dec 31, 202110.8%+32.2
FY2020Dec 31, 2020-21.4%−18.8
FY2019Dec 31, 2019-2.6%+6.3
FY2018Dec 31, 2018-9.0%+71.0
FY2017Dec 31, 2017-80.0%−89.8
FY2016Dec 31, 20169.8%−7.2
FY2015Dec 31, 201517.1%−2.4
FY2014Dec 31, 201419.5%+11.4
FY2013Dec 31, 20138.1%−2.7
FY2012Dec 31, 201210.9%−6.1
FY2011Dec 31, 201117.0%−7.0
FY2010Dec 31, 201024.0%+9.1
FY2009Dec 31, 200914.9%+4.6
FY2008Dec 31, 200810.3%−15.1
FY2007Dec 31, 200725.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-5.6%−16.5
Q1 FY2026Mar 31, 202616.4%+3.0
Q4 FY2025Dec 31, 202520.0%+20.7
Q3 FY2025Sep 30, 202519.7%+20.9
Q2 FY2025Jun 30, 202510.9%+11.0
Q1 FY2025Mar 31, 202513.3%+19.0
Q4 FY2024Dec 31, 2024-0.7%−17.6
Q3 FY2024Sep 30, 2024-1.2%−10.1
Q2 FY2024Jun 30, 2024-0.1%+16.7
Q1 FY2024Mar 31, 2024-5.7%−5.4
Q4 FY2023Dec 31, 202317.0%+41.2
Q3 FY2023Sep 30, 20238.9%−2.9
Q2 FY2023Jun 30, 2023-16.9%+8.7
Q1 FY2023Mar 31, 2023-0.4%+19.1
Q4 FY2022Dec 31, 2022-24.2%−26.1
Q3 FY2022Sep 30, 202211.8%−4.2
Q2 FY2022Jun 30, 2022-25.5%−40.4
Q1 FY2022Mar 31, 2022-19.5%−30.4
Q4 FY2021Dec 31, 20211.9%−7.2
Q3 FY2021Sep 30, 202116.0%+125.2
Q2 FY2021Jun 30, 202114.9%+10.4
Q1 FY2021Mar 31, 202110.9%+6.5
Q4 FY2020Dec 31, 20209.1%+5.8
Q3 FY2020Sep 30, 2020-109.2%−107.2
Q2 FY2020Jun 30, 20204.5%+19.9
Q1 FY2020Mar 31, 20204.4%+1.2
Q4 FY2019Dec 31, 20193.3%+74.9
Q3 FY2019Sep 30, 2019-2.0%−2.3
Q2 FY2019Jun 30, 2019-15.4%−15.1
Q1 FY2019Mar 31, 20193.2%−27.8
Q4 FY2018Dec 31, 2018-71.6%+169.5
Q3 FY2018Sep 30, 20180.4%−6.4
Q2 FY2018Jun 30, 2018-0.3%+100.0
Q1 FY2018Mar 31, 201831.0%+15.2
Q4 FY2017Dec 31, 2017-241.1%−239.0
Q3 FY2017Sep 30, 20176.7%−7.0
Q2 FY2017Jun 30, 2017-100.3%–
Q1 FY2017Mar 31, 201715.8%–
Q4 FY2016Dec 31, 2016-2.1%–
Q3 FY2016Sep 30, 201613.8%–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?